EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Role of proton pump inhibitors dosage and duration in Helicobacter pylori eradication treatment: Results from the European Registry on H. pylori management

Manuel Pabón-Carrasco iD, Alma Keco-Huerga, Manuel Castro-Fernández iD, Ilaria Maria Saracino, Giulia Fiorini, Dino Vaira, Ángeles Pérez-Aísa, Bojan Tepes iD, Laimas Jonaitis, Irina Voynovan, Alfredo J Lucendo, Ángel Lanas und 39 weitere

United European Gastroenterology Journal · 2024

DOI: 10.1002/ueg2.12476 ↗

Kurz gefasst

Fachartikel in der Zeitschrift United European Gastroenterology Journal, 2024. Verfasst von Manuel Pabón-Carrasco und 50 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Hospital de Valme, Sevilla, Spain. Hauptthemen laut MEDLINE: Helicobacter pylori, Helicobacter Infections. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Helicobacter and Microbiota Study Group (EHMSG), Spanish Association of Gastroenterology (AEG), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Management of Helicobacter pylori ( H. pylori ) infection requires co‐treatment with proton pump inhibitors (PPIs) and the use of antibiotics to achieve successful eradication.

Aim

To evaluate the role of dosage of PPIs and the duration of therapy in the effectiveness of H. pylori eradication treatments based on the ‘European Registry on Helicobacter pylori management’ (Hp‐EuReg).

Methods

Hp‐EuReg is a multicentre, prospective, non‐interventionist, international registry on the routine clinical practice of H. pylori management by European gastroenterologists. All infected adult patients were systematically registered from 2013 to 2022.

Results

Overall, 36,579 patients from five countries with more than 1000 patients were analysed. Optimal (≥90%) first‐line‐modified intention‐to‐treat effectiveness was achieved with the following treatments: (1) 14‐day therapies with clarithromycin‐amoxicillin‐bismuth and metronidazole‐tetracycline‐bismuth, both independently of the PPI dose prescribed; (2) All 10‐day (except 10‐day standard triple therapy) and 14‐day therapies with high‐dose PPIs; and (3) 10‐day quadruple therapies with clarithromycin‐amoxicillin‐bismuth, metronidazole‐tetracycline‐bismuth, and clarithromycin‐amoxicillin‐metronidazole (sequential), all with standard‐dose PPIs. In first‐line treatment, optimal effectiveness was obtained with high‐dose PPIs in all 14‐day treatments, in 10‐ and 14‐day bismuth quadruple therapies and in 10‐day sequential with standard‐dose PPIs. Optimal second‐line effectiveness was achieved with (1) metronidazole‐tetracycline‐bismuth quadruple therapy for 14‐ and 10 days with standard and high‐dose PPIs, respectively; and (2) levofloxacin‐amoxicillin triple therapy for 14 days with high‐dose PPIs. None of the 7‐day therapies in both treatment lines achieved optimal effectiveness.

Conclusions

We recommend, in first‐line treatment, the use of high‐dose PPIs in 14‐day triple therapy and in 10‐or 14‐day quadruple concomitant therapy in first‐line treatment, while standard‐dose PPIs would be sufficient in 10‐day bismuth quadruple therapies. On the other hand, in second‐line treatment, high‐dose PPIs would be more beneficial in 14‐day triple therapy with levofloxacin and amoxicillin or in 10‐day bismuth quadruple therapy either as a three‐in‐one single capsule or in the traditional scheme.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Helicobacter pyloriHelicobacter InfectionsAdultHumansProton Pump InhibitorsMetronidazoleClarithromycinLevofloxacinBismuthProspective StudiesDrug Therapy, CombinationAnti-Bacterial AgentsAmoxicillinTetracyclineRegistries

Stichwörter der Autor:innen

Helicobacter pyloriamoxicillinbismuthclarithromycinlevofloxacinmetronidazoleproton pump inhibitortetracyclinetinidazoletreatment

Substanzen

Proton Pump InhibitorsMetronidazoleClarithromycinLevofloxacinBismuthAnti-Bacterial AgentsAmoxicillinTetracycline

Autor:innen und Institutionen

  • Department of Gastroenterology, Hospital de Valme, Sevilla, Spain.
  • IRCCS AOU di Bologna, Bologna, Italy.
  • Agencia Sanitaria Costa del Sol, Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Marbella, Spain.
  • Department of Gastroenterology, AM DC Rogaska, Rogaska Slatina, Slovenia.
  • Institute for Digestive Research, Lithuanian University of Health Sciences, Kaunas, Lithuania.
  • Department of Gastroenterology, Lithuanian University of Health Sciences, Kaunas, Lithuania.

ORCID-Profile: Manuel Pabón-Carrasco, Manuel Castro-Fernández, Bojan Tepes, Luis Rodrigo, Igor Bakulin, Sergey Alekseenko, Antonietta G Gravina, Blas José Gómez Rodríguez, Dmitry S Bordin, Javier P Gisbert

Förderung

  • European Helicobacter and Microbiota Study Group (EHMSG)
  • Spanish Association of Gastroenterology (AEG)
  • Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd)
  • European Union programme HORIZON
  • UK Research and Innovation
  • European Union programme EU4Health
  • Diasorin

Zitieren

APA

Pabón-Carrasco, M., Keco-Huerga, A., Castro-Fernández, M., Saracino, I. M., Fiorini, G., Vaira, D., Pérez-Aísa, Á., Tepes, B., Jonaitis, L., Voynovan, I., Lucendo, A. J., Lanas, Á., Martínez-Domínguez, S. J., Almajano, E. A., Rodrigo, L., Vologzanina, L., Brglez Jurecic, N., Denkovski, M., Bujanda, L., …, & Hp-EuReg Investigators (2024). Role of proton pump inhibitors dosage and duration in Helicobacter pylori eradication treatment: Results from the European Registry on H. pylori management. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.12476

Vancouver

Pabón-Carrasco M, Keco-Huerga A, Castro-Fernández M, Saracino IM, Fiorini G, Vaira D, et al. Role of proton pump inhibitors dosage and duration in Helicobacter pylori eradication treatment: Results from the European Registry on H. pylori management. United European Gastroenterology Journal. 2024. doi:10.1002/ueg2.12476

BibTeX
@article{PabnCarrasco2024,
  author = {Pabón-Carrasco, Manuel and Keco-Huerga, Alma and Castro-Fernández, Manuel and Saracino, Ilaria Maria and Fiorini, Giulia and Vaira, Dino and Pérez-Aísa, Ángeles and Tepes, Bojan and Jonaitis, Laimas and Voynovan, Irina and Lucendo, Alfredo J and Lanas, Ángel and Martínez-Domínguez, Samuel J and Almajano, Enrique Alfaro and Rodrigo, Luis and Vologzanina, Ludmila and Brglez Jurecic, Natasa and Denkovski, Maja and Bujanda, Luis and Abdulkhakov, Rustam A and Huguet, Jose M and Fernández-Salazar, Luis and Alcaide, Noelia and Velayos, Benito and Silkanovna Sarsenbaeva, Aiman and Zaytsev, Oleg and Ilchishina, Tatiana and Barrio, Jesús and Bakulin, Igor and Perona, Monica and Alekseenko, Sergey and Romano, Marco and Gravina, Antonietta G and Núñez, Óscar and Gómez Rodríguez, Blas José and Ledro-Cano, Diego and Pellicano, Rinaldo and Bogomolov, Pavel and Domínguez-Cajal, Manuel and Almela, Pedro and Gomez-Camarero, Judith and Bordin, Dmitry S and Gasbarrini, Antonio and Kupčinskas, Juozas and Cano-Català, Anna and Moreira, Leticia and Nyssen, Olga P and Mégraud, Francis and O'Morain, Colm and Gisbert, Javier P and Hp-EuReg Investigators, Hp-EuReg Investigators},
  title = {Role of proton pump inhibitors dosage and duration in Helicobacter pylori eradication treatment: Results from the European Registry on H. pylori management},
  journal = {United European Gastroenterology Journal},
  year = {2024},
  doi = {10.1002/ueg2.12476}
}
Kostenlos starten →